Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 220

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 220
---
Total current liabilities                                  7,222                1,311    
Non-current liabilities                                                                  
Deferred revenues (note 6)                                   914                    -    
Lease liabilities (note 14)                                2,039                1,399    
Employee future benefits (note 15)                        11,734                    -    
Total non-current liabilities                             14,687                1,399    
Total liabilities                                         21,909                2,710    
Shareholders’ equity                                                                     
Share capital (note 18)                                   22,486               13,517    
Contributed surplus (note 18)                              4,268                3,874    
Retained earnings (accumulated deficit)                  (12,110   )            4,356    
Accumulated other comprehensive loss                      (1,483   )             (712   )
Total shareholders’ equity                                13,161               21,035    
Total liabilities and shareholders’ equity                35,070               23,745    
 
Commitments (note 26)
 Subsequent event (note 28)
 
The accompanying notes are an integral part of these consolidated financial statements.
 
Approved by the Board of Directors
 

               /s/                           /s/          
          Ronnie Miller                  Pierre Labbé     
----------------------------------------------------------
Ronnie Miller, Chair of the Board   Pierre Labbé, Director

F-7
---
COSCIENS Biopharma Inc.
 Consolidated Statements of Changes in Shareholders’ Equity
 For the years ended December 31, 2024, 2023 and 2022
 
(in thousands of US dollars)
 

                                                                                                            Share capital        Contributed Surplus         Retained earnings         Accumulated other comprehensive income (loss)           Total        
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                            $                           $   $                                                                           $                  $
Balance - January 1, 2022                                                                                           13,389                      3,664                     4,392                                                   491             21,936    
Net income                                                                                                          -                               -                     3,448                                -                                   3,448    
Other comprehensive loss:                                                                                                                                                                                                                                   
Foreign currency translation adjustments                                                                            -                               -                         -                                (1,694                   )         (1,694   )
Comprehensive (loss) income                                                                                                                                               3,448                                (1,694                   )          1,754    
Stock options exercised                                                                                                107                        (43   )                     -                                -                                      64    
Share-based compensation costs                                                                                      -